Biomarkers in cancer-associated thrombosis

Roche live webinar featuring World Thrombosis Day campaign

Tuesday, 29th of March 2022

12:00 - 12:55pm CEST/ 6:00 - 6:55pm SGT/CST


The World Thrombosis Day (WTD) campaign seeks to increase global awareness of thrombosis, including its causes, risk factors, signs/symptoms and evidence-based prevention and treatment. This closely aligns with Roche’s dedication and commitment to innovating diagnostics by developing healthcare solutions to improve patient’s care.1


In partnership with WTD and led by expert researchers, we look at the predictive role of biomarkers in cancer-associated thrombosis. Venous thromboembolism (VTE) is a common complication in patients with cancer. Latest research indicates that cancer patients are at four times higher risk than the general population of developing serious blood clots. This increased risk of thrombosis is driven and modified by risk factors including cancer-specific factors such as type, histology, and stage of the malignancy, cancer treatment and certain biomarkers. 2


The prevalence and incidence of cancer-associated thrombosis (CAT) is rising 3,4, which leads to an increasing need for VTE risk assessment models, to be able to identify patients who would benefit from anticoagulation. Coagulation biomarkers are not only very useful to determine the thrombotic risk, but find its use as well in monitoring cancer progression and overall prognosis. 5


Expand your knowledge and engage in live discussions with Prof. Anna Falanga and Cinzia Giaccherini on cancer-associated thrombosis (CAT) in support of the World Thrombosis Day campaign.



  3. Heit JA, et al. J Thromb Thrombolysis 2016;41(1):3–14.
  4. Farge D, et al. Lancet Oncol 2019;20(10):e566–81.
  5. Ay C, et al. Thromb Haemost. 2017 26;117(2):219–30
The predictive role of biomarkers in cancer-associated thrombosis

The predictive role of biomarkers in cancer-associated thrombosis


Tuesday, 29th of March 2022

12:00 - 12:55pm CEST

6:00-6:55pm SGT/CST


The predictive role of biomarkers in cancer-associated thrombosis

12:00 - 12:20

CAT risk prediction and prevention

Prof. Anna Falanga


12:20 - 12:40

Lung cancer: biomarkers for CAT prediction and disease prognosis

Cinzia Giaccherini


12:40 - 12: 55

Q&A, session close

Meet the speakers

Anna Falanga

Anna Falanga

MD, Professor of Hematology


Anna Falanga, MD, is full professor of Hematology at University of Milan Bicocca and Chief of the Department of Immunohematology and Transfusion Medicine and the Thrombosis and Hemostasis Center, at the Hospital Papa Giovanni XXIII, in Bergamo, Italy. She has authored more than 300 publications and is guest editor of 21 volumes and she is an expert in the field of cancer and thrombosis.

She has an active role in several professional societies, including the International Society of Thrombosis and Haemostasis (ISTH), the European Hematology Association (EHA) and the Italian Society of Thrombosis and Hemostasis (SISET). She received the BACH Investigator Award of the ISTH (2009), and the “Harold R. Roberts Medal 2015” of the SSC of ISTH (2015).

Cizia Giaccherini

Cinzia Giaccherini

MSc, Researcher


Cinzia Giaccherini is a research biologist with more than 10 years of experience at the Hemostasis and Thrombosis Laboratory of the Immunohematology and Transfusion Medicine division at Papa Giovanni XXIII Hospital in Bergamo (Italy). She is also attending a postgraduate specialization in Medical Statistics and Biometrics at the University of Milan.

Her research field includes the study of coagulation in different diseases, and she is an author of different publications in this area. She mainly deals with studying thrombotic biomarkers in cancer patients for prediction of cancer-associated thrombosis and disease prognosis.

small banner CAT